SMS Pharmaceuticals Limited — PPTs, 12-11-2024: Investor Presentation

**Financial Highlights:**

SMS Pharmaceuticals reported a strong quarterly performance for Q2FY25, achieving revenue from operations of ₹196.75 crore, an 18% increase YoY. The EBITDA stood at ₹31.47 crore, reflecting a 13% growth, with a stable EBITDA margin of 16%. Profit After Tax (PAT) also saw a robust 20% uptick YoY, reaching ₹14.10 crore.

**Strategic Initiatives and Growth Drivers:**

The company received EDQM certification, enhancing its capability to supply Ibuprofen across Europe. Upcoming commercialization efforts are expected to contribute positively. With ongoing capex investments aimed at long-term growth and efficiency, expectations for revenue growth remain around 20% for FY25.

**Business Developments:**

The firm continues to enhance its product pipeline, aiming to launch 8-10 new products in the next 12-18 months. Focus on backward integration is anticipated to optimize costs, alongside a strategy to ramp up key APIs.

**Market Position and Competitive Advantage:**

SMS Pharmaceuticals holds a leading position in the specialty APIs market, backed by extensive regulatory approvals and a solid domestic and export mix. The company's strong R&D focus and diversified product offerings enhance its competitive edge.

**Investor Implications:**

With a robust revenue growth trajectory and increasing profitability, SMS Pharmaceuticals has a positive outlook. The strategic initiatives planned for the coming months position the company well for sustained growth and market leadership, making it a notable entity for potential investment consideration.